Biosynex Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Biosynex Aktie has already paid €2.00 in dividends. The last payout was in May 2022.

Financials

In the last quarter, Biosynex Aktie had revenue of €45.3m and net profit of -€4.2m

(EUR)	June 2026	YoY
Revenue	45.3m	-
Gross profit	-1.1m	-
Net profit	-4.2m	-
EBITDA	-1.6m	-

Fundamentals

Metric	Value
Market capitalization	€15.3m
Number of shares	18.43m
52-week high/low	€1.57 - €0.46
Dividends	No
Beta	0.78
P/E ratio	-1.14
PEG ratio	-0.01
P/B ratio	0.48
P/S ratio	0.17

Company profile

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.